Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D03SLK
|
|||
| Former ID |
DNCL001610
|
|||
| Drug Name |
SAR292833
|
|||
| Indication | Pain [ICD-11: MG30-MG3Z] | Phase 2 | [1] | |
| Insulin-dependent diabetes [ICD-11: 5A10] | Investigative | [2] | ||
| Company |
Sanofi-aventis; Glenmark Pharmaceuticals
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Transient receptor potential cation channel V3 (TRPV3) | Target Info | Modulator | [1] |
| KEGG Pathway | Inflammatory mediator regulation of TRP channels | |||
| Reactome | TRP channels | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Pharmacological profiling of the TRPV3 channel in recombinant and native assays. Br J Pharmacol. 2014 May;171(10):2631-44. | |||
| REF 2 | The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.